Pfizer Reports Positive Data From Phase 3 Trial Of Talzenna/Xtandi Combo

NEW YORK CITY (dpa-AFX) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with

Related Keywords

Dennis Riedl ,Pfizer ,Drug Administration ,Priority Review ,Reports ,Positive ,Data ,Rom ,Hase ,Trial ,Talzenna ,Xtandi ,Combo ,